ReviewWorld journal of cardiology2014
African Americans, hypertension and the renin angiotensin system.
Review in World journal of cardiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide.Hypertension (Dallas, Tex. : 1979) · 2017Pooled it
- Renin-Angiotensin-Aldosterone Profiles in Pregnant Women With Chronic Hypertension.Hypertension (Dallas, Tex. : 1979) · 2018Trial
- Comparison of Angiotensin II (GiaprezaBiomedicines · 2025Article
- Hypertension in Sub-Saharan Africa: Burden, Barriers and Priorities for Improving Treatment Outcomes.Circulation research · 2025Review
- Clinical outcomes of pharmacological therapies for heart failure in Black vs. White populations: a meta-analysis of randomized controlled trials of heart failure treatment.Frontiers in cardiovascular medicine · 2025Article
- Impact of short-term (24 h) blood pressure variability on 30-days clinical outcomes of acute strokes at two tertiary hospitals in Dar-es-Salaam.Frontiers in stroke · 2025Article
- Exploratory Studies on RNAi-Based Therapies Targeting Angiotensinogen in Hypertension: Scoping Review.Journal of personalized medicine · 2024Review
- Outpatient management of essential hypertension: a review based on the latest clinical guidelines.Annals of medicine · 2024Review
- Inconclusiveness of psychometric testing of medication adherence questionnaires.European journal of clinical pharmacology · 2024Article
- Transcriptome Study of 2 Black Cohorts RevealsJournal of the American Heart Association · 2024Article
- The association of aldosterone and endothelin-1 with incident diabetes among African Americans: The Jackson Heart Study.Endocrine and metabolic science · 2023Article
- Racial disparities in characteristics and outcomes of patients undergoing mitral transcatheter edge-to-edge repair.Frontiers in cardiovascular medicine · 2023Article
- Review
- Lisinopril Mitigates Radiation-Induced Mitochondrial Defects in Rat Heart and Blood Cells.Frontiers in oncology · 2022Article
- Combining Neprilysin Inhibitor With ATFrontiers in pharmacology · 2021Article
- Pharmacological approaches to the treatment of COVID-19 patients.Journal of translational science · 2020Article
- Sars-CoV-2 and black population: ACE2 as shield or blade?Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2020Article
- Coronavirus Disease-2019 in Heart Transplant Recipients in Southeastern Michigan: A Case Series.Journal of cardiac failure · 2020Article
- Does race impact functional outcomes in patients undergoing robotic partial nephrectomy?Translational andrology and urology · 2020Article
- COVID's Razor: RAS Imbalance, the Common Denominator Across Disparate, Unexpected Aspects of COVID-19.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
African Americans have exceptionally high rates of hypertension and hypertension related complications. It is commonly reported that the blood pressure lowering efficacy of renin angiotensin system (RAS) inhibitors is attenuated in African Americans due to a greater likelihood of having a low renin profile. Therefore these agents are often not recommended as initial therapy in African Americans with hypertension. However, the high prevalence of comorbid conditions, such as diabetes, cardiovascular and chronic kidney disease makes treatment with RAS inhibitors more compelling. Despite lower circulating renin levels and a less significant fall in blood pressure in response to RAS inhibitors in African Americans, numerous clinical trials support the efficacy of RAS inhibitors to improve clinical outcomes in this population, especially in those with hypertension and risk factors for cardiovascular and related diseases. Here, we discuss the rationale of RAS blockade as part of a comprehensive approach to attenuate the high rates of premature morbidity and mortality associated with hypertension among African Americans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.